Congratulations to Ilia Tikhomirov, Class of 2007

Tuesday, April 10, 2012 - 2:00pm

Ilia Tikhomirov, President and CEO of AvidBiologics Inc., (MBiotech Class of 2007) announced on April 5 that AvidBiologics Inc. has raised Series A capital from private investors and expanded its board of directors. The funds will be used to advance the company's antibody-drug conjugate (ADC) programs into Investigational New Drug (IND) studies. 

AvidBiologics Inc. is a privately-held biopharmaceutical company specializing in the development of oncology products. 

"AvidBiologics is commercializing novel ADC molecules designed to be highly effective and safe anti-cancer treatments. This investment validates commercial prospects of our antibody-engineering technology and ADC candidates designed using this platform and in collaboration with highly-regarded scientific centers of excellence", said Ilia Tikhomirov, AvidBiologics’ CEO. 

Read the full press release here.

Since graduating from the Master of Biotechnology Program in 2007, Ilia has gained significant experience in managing oncology R&D and business development. He was formerly the Associate Director of Science at YM BioSciences Inc. and is a co-inventor of AvidBiologics’ technology. 

Congratulations Ilia!